It is reported that PLC patients with high phosphorylated MAPK3 (also called ERK1) had significantly higher cancer recurrence and worse OS [50], and the impact of MAPK3 on survival was also verified by the survival curve in this study. This evidence concerns the gene HSPG2 and cancer.